ReviewEJNMMI reports2025
Advances in clinical neuro-oncology research on integrin PET imaging.
Review in EJNMMI reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Synchronous PET/MR imaging and visualizing penetration of nanomedicine within tumor based onJournal of nanobiotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAngiogenesis plays a pivotal role in the progression of neuro-oncological diseases, mediated by integrin receptors on endothelial and tumor cells. Radiolabeled RGD peptides, targeting integrins such as αvβ
methodsA systematic literature search was conducted in PubMed, EMBASE, and Cochrane Library until November 2024, identifying relevant studies using RGD-based tracers in neuro-oncological imaging. Data on patient demographics, tumor types, imaging protocols, tracer characteristics, and outcomes were extracted. Methodological quality was assessed using the QUADAS-2 tool.
resultsEight studies, encompassing 112 patients with primary and secondary brain tumors, were included. All studies utilized αvβ
conclusionRGD PET imaging is a promising tool for neuro-oncology, providing enhanced diagnostic accuracy and valuable prognostic insights. Future research should focus on integrating molecular imaging findings into personalized treatment strategies and exploring novel RGD tracers for broader clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.